PIM1 and prostate cancer: Due to a dose-limiting hazard in ventricular electrical cycle (QTc) lengthening in patients with relapsed/refractory leukemia, the first was discontinued prior to enrolment, and the second inhibitor, which was effective against all three PIM kinases, was discontinued for treating patients with prostate cancer and lymphoma because of its cardiac toxicity.